Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $112.8 million.

  • IDEAYA Biosciences' Cash & Equivalents rose 3371.38% to $112.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $112.8 million, marking a year-over-year increase of 3371.38%. This contributed to the annual value of $112.8 million for FY2025, which is 3371.38% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Cash & Equivalents of $112.8 million as of Q4 2025, which was up 3371.38% from $298.9 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Cash & Equivalents high stood at $400.3 million for Q3 2024, and its period low was $49.1 million during Q2 2022.
  • In the last 5 years, IDEAYA Biosciences' Cash & Equivalents had a median value of $108.4 million in 2021 and averaged $130.7 million.
  • In the last 5 years, IDEAYA Biosciences' Cash & Equivalents skyrocketed by 28562.97% in 2021 and then crashed by 5956.84% in 2022.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Cash & Equivalents stood at $92.0 million in 2021, then fell by 25.44% to $68.6 million in 2022, then surged by 128.78% to $157.0 million in 2023, then plummeted by 46.26% to $84.4 million in 2024, then soared by 33.71% to $112.8 million in 2025.
  • Its last three reported values are $112.8 million in Q4 2025, $298.9 million for Q3 2025, and $114.6 million during Q2 2025.